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High-dose chemotherapy alone and sometimes 
together with radiotherapy with following a�tologo�s 
transplantation of hematopoietic stem cells �HSCs� is 
�sed for treatment of patients with advanced stages 
or relapses of malignant diseases. However� recon-
stit�tion of ne�trophil and platelet cell n�mber after 
a�totransplantation of HSCs is delayed for abo�t 5% 
of patients. In most cases it co�ld be explained by low 
dose of transplanted CD�4+ cells per kg of patient’s 
body weight [�� �].
Dimitri et al observed that the n�mber and q�ality 
of mobilized peripheral blood stem cells �PBSC� was 
low in patients that received m�ltiple ro�nds of che-
motherapy and grafts with low n�mbers of HSCs. Poor 
q�ality of HSCs was the ca�se of graft fail�re �pon their 
a�tologo�s inf�sion [�]. 
Recently� some approaches were s�ggested 
to solve this problem. One of them is a generally 
accepted proced�re of repeated attempts of PBSC 
collection or aspiration of considerable vol�me 
of bone marrow �BM� in case of ins�fficient CD�4+ cell 
n�mber in transplant at the time of primary collection 
of PBSC. Another approach incl�des expansion of 
hematopoietic stem cells ex vivo. This is an attractive 
method to improve hematological recovery or red�ce 
graft size. However� altho�gh clinical trials indicated 
that total n�mber of CD�4+ cells and primitive stem 
cells in PBSC can be s�ccessf�lly expanded in vitro� 
hematopoietic recovery by �sing s�ch grafts is not im-
proved [4� 5]. This co�ld be explained by the red�ction 
of stem cells ability to home to the bone marrow after 
inc�bations with several cytokine combinations� which 
leads to the loss of their ability to repop�late the he-
matopoietic system of irradiated recipients [6]. 
At the present time� there is another highly attrac-
tive approach to red�ce the hematopoiesis reconstit�-
tion period after transplantation of HSCs — the sim�l-
taneo�s a�totransplantation of mesenchymal stem 
cells �MSCs�. Mesenchymal stem  cells are prec�rsors 
of stromal stem cells� osteoblasts� adipocyts� en-
dothelial cells� which form regions of hematopoietic 
ind�ctive environment in bone marrow� th�s� s�pport-
ing the prod�ction of le�cocytes� red cells and platelets 
[7� �]. From one hand� their impact on hematopoiesis 
prec�rsors is realized by secretion of sol�ble cyto-
kines� chemokines� peptides� mediators and hor-
mones. From the other hand� MCSs form the extra-
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Aim: To test the ability of cultured mesenchymal stem cells (MSCs) from bone marrow (BM) of children with oncohematological disea­
ses after chemotherapy and radiation to support proliferation and self renewal of hematopoietic cells in vitro. Methods: BM samples 
of 8 patients and 9 healthy children­donors used for MSCs preparation applying techinque of expansion in vitro. CD34+ cells were 
isolated from BM of donors. The ability of MSCs to maintain hematopoietic stem cells (HSCs) proliferation was tested in semisolid 
methylcellulose medium and in liquid long­term­culture (LTC) medium. Results: The presence of MSCs derived from BM of patients 
in methylcellulose medium induced 2­fold increase of the number of commited myeloid progenitors without cytokines, 7­fold increase 
together with growth factors and 14­fold increase of the amount of earlier pluripotent hematopoietic precursor cells (CFU­GEMM) 
compared to expansion of HSCs without MSCs and cytokines. The presence of MSCs layer of patients in liquid LTC medium sig­
nificantly promoted the hematopoietic cells proliferation rate, measured on 7th, 14th and 21st day. The total number of cells was 
multiplied 161.2­fold on 21st day as compared to 116.4­fold without MSCs layer. In the presence of MSCs layer, we detected the 
increase of proportion of bipotent CFU­GM precursors from 4% to 11% and pluripotent CFU­GEMM precursors from 0.1% to 0.6% 
in population of HSCs. In both types of experiments the capacity of patients’ MSCs to support HSCs proliferation and self renewal 
was the same as for healthy donors’ MSCs. Conclusion: In this study, МSCs were isolated from BM of children with malignancies 
after high­dose chemotherapy or radiation. The ability of these MSCs to maintain hematopoiesis in vitro was tested. It was shown 
that co­transplantation of autologous MSCs is a good way to improve hematopoietic stem cells engraftment and reduce a period of 
granulocytopenia after autologous HSCs transplantation in case of insufficient CD34+ cell number in autologous transplant.
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cell�lar matrix from collagen� fibronectin and laminin 
molec�les� which provide adhesion of hematopoietic 
cells. Stromal cells contin�o�sly synthesize colony 
stim�lating factor �CSF�� interle�kin-6 �IL-6�� IL-�� 
IL-7� IL-�� SCF� Flt-�-ligand� GM-CSF� thrombopoietin� 
ins�lin-like growth factor� transforming growth factor 
�TGF�� th�s� s�pporting the maintenance of the de-
termined level of blood cells n�mber. IL-� is the main 
cytokine prod�ction ind�ctor� and TGF is able to inhibit 
hematopoiesis [9]. The ability of MSCs to s�pport he-
matopoiesis in vitro has been shown by many a�thors 
in sim�ltaneo�s c�ltivation of MSCs and HSCs [��]. 
The capacity of stromal cells to s�pport the expansion 
of primitive hematopoietic progenitors for more than 
�� weeks was revealed [��]. 
Until recently� practically all of the investigations of 
MSCs effect on hematopoietic prec�rsor cells prolife-
ration and self-renewal were carried o�t by �sing 
stromal cells layer derived from bone marrow MSCs 
of healthy donors. Therefore� it is important to st�dy 
f�nctional potential of mesenchymal stem cells derived 
from bone marrow of children� who are the candidates 
for HSCs transplantation after high dose chemo-
therapy. We investigated the ability of c�lt�red MSCs 
from patients’ BM to s�pport proliferation and self-
renewal of hematopoietic cells in vitro. It can be of 
great importance for creation of therape�tical strategy 
of a�tologo�s MSCs application for hematopoiesis 
s�pport and ne�tropenia period red�ction after HSCs 
a�tologo�s transplantation for children with ins�f-
ficiency of CD�4+ cell n�mber in graft.
MATERIALS AND METHODS
Materials. Bone marrow samples of � patients 
with IV stage of non-Hodgkin’s lymphoma� Hodgkin 
disease and Ewing sarcoma have been �sed. Protocol 
of treatment of these patients incl�ded a�tologo�s 
transplantation of HSCs. Comparative analysis has 
been performed by eval�ation of bone marrow sam-
ples of 9 children-donors of hemopoietic stem cells 
for allogenic transplantation.*
BM cell preparation. Samples of BM were obtained 
from allogenic or a�tologo�s bone marrow transplants. 
Monon�clear cells �MNCs� were isolated by centrif�ga-
tion on a Ficoll-Hypaq�e gradient �density �.�77 g/ml� 
�Sigma� USA� at 4�� g for �5 min� washed twice in Hanks 
Balanced Sold Sol�tion �HBSS� �Sigma� USA�. 
CD34+ cells separation. CD�4+ cells were derived 
from bone marrow of healthy donors. The proced�re 
of CD�4+ cells processing from fraction of bone marrow 
monon�clear cells was carried by means of H�man CD�4 
Selection Kit for positive selection �StemCell Technolo-
gies� Canada� according to man�fact�rer’s protocol.
Human mesenchymal cells preparation. Mono-
n�clear cells were s�spended in Iscove Modified D�l-
becco Medi�m �IMDM� with ��% fetal bovine ser�m 
�FBS� �Sigma� USA� at concentration of � х ��6/ml 
and were transferred to tiss�e c�lt�re flask �Sarstedt� 
* Patients provided written consent to perform the study, and research 
was approved by the Ethic Committee of the Research Center.
Germany� at density �.5 х ��6/cm�. Cells were c�lt�red 
at �7 C with 5% CO�� in h�midified atmosphere. When 
cells achieved ���9�% of confl�ence� the adherent 
layer was washed with HBSS to remove resid�al FBS 
and was detached with �.�5% trypsin-EDTA sol�tion 
�Sigma� USA�. Then MSCs were washed in IMDM 
with ��% fetal bovine ser�m and �.6�� х ��6 cells were 
transferred to a new �5 sm2 flask �I passage�. When 
~ 9�% confl�ent layer was prod�ced� the manip�lation 
was repeated again. For eval�ation of mesenchymal 
cells infl�ence on hematopoietic cell growth we �sed 
the same MSCs from II�IV passages for the healthy 
donors’ and patients’ preparations.
Long-term culture hematopoietic and mesen-
chymal stem cells. Mesenchymal cells were seeded 
at concentration of �.5 х ��5/well into �4-wells plates. 
Cells were c�lt�red in IMDM-medi�m s�pplemented 
with ��% FBS overnight at �7 °C in 5% CO�. Monolayer 
of cells was treated with �% gl�taraldehyde or irradia-
ted at �� Gy to stop proliferation of mesenchymal cells. 
Then� p�rified donors’ CD�4+ cells �� x ��4/ml� were 
added to the wells. Cells were c�lt�red in IMDM s�pple-
mented with �5% FBS� � mM L-gl�tamine and �-mer-
captoethanol in presence and witho�t a cocktail of re-
combinant h�man cytokines. We �sed following growth 
factors �GF�: IL-� ��� ng/ml�� IL-6 ��� U/ml�� stem cell 
factor SCF �5� ng/ml�� Flt-�-ligand ���� ng/ml�. Cells 
were inc�bated for �� days in standard conditions with 
weekly replacement of half of the medi�m. Cells were 
co�nted and their viability was analyzed at 7th� �4th 
and ��st day.
Semisolid assay of clonogenic progenitors 
in the different conditions. Pl�ripotent and line-
committed hematopoietic prec�rsor cells form dif-
ferent types of colonies or «colony-forming �nits» 
�CFU� in short-term c�lt�re. Myeloid line-committed 
prec�rsors form colony-forming �nits gran�locyte 
�CFU-G�� CFU — macrophage �CFU-M�; bypotential 
prec�rsor forms CFU — gran�locyte-macrophage 
�CFU-GM�; pl�ripotential hematopoietic prec�rsor 
forms CFU- gran�locyte — erythroid-monocyte-
megakaryocyte �CFU-GEMM� and erythroid prec�rsor 
forms b�rst-forming �nits erythroid �BFU-E�. Experi-
ments were performed in six parallel variants. Initially� 
CD�4+ cells were s�spended at a concentration � x 
��4 cells/ml in � ml complete methylcell�lose me-
di�m ��% methylcell�lose in IMDM� ��% fetal bovine 
ser�m��% alb�min� � mM L-gl�tamine� witho�t and 
with presence of colonystim�lating growth factors: 
�� ng/mL recombinant h�man IL-� �rhIL-��; �� ng/mL 
recombinant h�man gran�locyte macrophage — CSF 
�rhGM-CSF�; 5� ng/mL recombinant h�man stem cell 
factor �rhSCF�; � U/mL h�man erythropoietin �Epo�. 
F�rther� each of the two variants of cells in methylcel-
l�lose medi�m were plated �� x ��4 cells/well in � ml� 
in presence and witho�t MSC layer derived from bone 
marrow of patients and from bone marrow of donors 
as a control in 6 wells of �4-wells plastic microplates. 
Plates were inc�bated at �7 °C with 5% C�� and ≥ 95% 
h�midity for �� days. N�mber of CFU-G� CFU-M� 
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CFU-GM� CFU-GEMM and BFU-E were scored mac-
roscopically at ��st day.
Statistical analysis. Statistical processing of 
data was performed with the statistical package 
STATISTICA � Ver 6.�. �Stat Soft Inc� USA�. Mann — 
Whitney U test was �sed to eval�ate significant diffe-
rences between samples of patients and donors. Wil-
coxon matched pairs test was �sed to eval�ate the fold 
increase of cells c�lt�red �nder different condition. 
RESULTS
Effect of MSCs on maintaining of CD34+ cells 
proliferation in semisolid medium. Research was 
performed �sing MSCs derived from bone marrow 
of � patients and 9 healthy donors and hematopoi-
etic CD�4+ cells selected from samples of healthy 
donors. Eval�ation of clonogenic progenitors content 
was carried o�t after c�ltivation of CD�4+ cells in 
methylcell�lose medi�m for �� days in each of 6 vari-
ants: hematopoietic cells as the negative control� he-
matopoietic cells with MSCs of donors� hematopoietic 
cells with MSCs of patients� hematopoietic cells with 
growth factors �GF�� hematopoietic cells with GF and 
MSCs of donors� and hematopoietic cells with GF and 
MSCs of patients. All types of myeloid line colonies� 
i. e. CFU-G� CFU-M� CFU-GM were termed “myeloid 
progenitors”. The level of variability in myeloid pro-
genitor cells n�mber �nder different c�lt�ral condi-
tions was relative to myeloid progenitor’s n�mber in 
negative control �Fig. �� a�. Analysis of res�lts showed 
relative increase in myeloid progenitors n�mber when 
CD�4+ cells were c�lt�red in the presence of GF 
alone� MSCs alone or GF and MSCs sim�ltaneo�sly. 
The presence of both patients’ and donors’ MSCs in 
methylcell�lose medi�m res�lted in �.�6 ± �.�5-fold 
�p < �.�5� and in �.�5 ± �.� �p < �.�5� — fold increase 
in the n�mber of myeloid progenitors cells respectively 
as compared with negative control� while adding only 
growth factors in methylcell�lose medi�m increased 
CFU-GM n�mber �.� ± �.6�-fold. Hematopoietic stem 
cells proliferated more intensively in the sim�ltaneo�s 
presence of GF and MSCs in growth medi�m. Myeloid 
progenitors n�mber on average was 7.�� ± �.�4-fold 
higher in the presence of patients’ MSCs �p < �.��� 
and 7.�� ± �.�5-fold higher in the presence of do-
nors’ MSCs as compared with the negative control 
�p < �.���. The significant difference between impacts 
of patients and donors’ MSCs on proliferation of the 
myeloid prec�rsor cells was not detected.
Infl�ence of both patients’ and donors’ MSCs 
on the earlier pl�ripotent hematopoietic prec�rsor 
cells proliferation was eval�ated CFU-GEMM n�mber 
in each of 6 variants. The Fig. �� b presents relative 
increase in CFU-GEMM n�mber in case of GF alone or 
GF and MSCs sim�ltaneo�sly added with CD�4+cells. 
We didn’t observe any CFU-GEMM n�mber expan-
sion when CD�4+ cells were c�lt�red in the presence 
of MSC witho�t GF. Maxim�m increase in CFU-GEMM 
n�mber was detected when GF and MSCs were added 
sim�ltaneo�sly as compared with variants of MSCs 
alone ��5.9 ± 7.� vs �.9 ± �.4 for donors �p < �.�5� 
and �4.�7 ± 6.9 vs �.9 ± �.� for patients �p < �.�5�� 
or GF alone ��5.9 ± 5.9 vs �.� ± �.� from donors 
�p < �.�5� and �4.�7 ± 6.9 vs 5.�� ± �.�6 from patients 
�p < �.�5��. 
Fig. 1. Effect of MSC derived from BM of patients with oncohe-
matological diseases on proliferation of CD�4+ cells in semisolid 
medi�m. MSCs derived from donors’ BM served as a control. 
� x ��4 of CD�4+ cells of healthy donors were c�lt�red in methyl-
cell�lose medi�m �nder different conditions: c�lt�re medi�m 
alone; with GF; with patients’ MSCs; with GF and patients’ MSCs; 
with donors’ MSCs; with GF and donors’ MSCs. Cells were c�l-
t�red for �� days and n�mber of CFU was scored. Each col�mn 
represents the fold increase of progenitors observed in six sepa-
rate variants� relative to n�mber of progenitors grown witho�t 
GF and MSCs: (a) Fold increase of total n�mber of CFU-G + 
CFU-M + CFU-GM and termed here as “myeloid progenitors”; 
(b) Fold increase of pl�ripotential prec�rsors cells �CFU-GEMM�. 
Wilcoxon matched pairs test was �sed for comparison of fold 
cells increase inside each gro�p �*p < �.�5� **p < �.���
Mann — Whitney U test was �sed to compare the 
effect of donors’ and patients’ MSCs on fold increase 
of hematopoietic cells’ n�mbers. It confirmed that 
MSCs derived from patients’ BM with statistical validi-
ty had the same s�pporting effect on the proliferation 
of the pl�ripotent hematopoietic prec�rsor cells �CFU-
GEMM� as donors’ MSCs.
Influence of MSCs on maintaining of CD34+ 
cells proliferation in liquid long-term cell culture. 
In order to investigate the infl�ence of MSCs on he-
matopoietic cells expansion in liq�id complete growth 
medi�m� two experiments with fo�r c�ltivation variants 
were performed: �� �n = �� — only CD�4+ cells� CD�4+ 
cells on MSCs layer of healthy donors� CD�4+ cells 
with growth factors� CD�4+ cells with growth factors on 
MSCs layer of healthy donors; �� �n = �� — only CD�4+ 
cells� CD�4+ cells on MSCs layer of patients� CD�4+ cells 
with GF� CD�4+ cells with GF on MSCs layer of patients. 
For both experiments� CD�4+ cells were isolated from 
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bone marrow of healthy donors’ samples� and the ini-
tial concentrations of these cells were � х ��4 for each 
c�ltivation variants. Kinetics of СD�4+ cells proliferation 
for different variants is presented on Fig. �. The absol�te 
cells n�mbers from � variants of both experiments� when 
MSCs layer was absent and CD�4+cells were grown only 
in c�lt�re medi�m� or CD�4+ cells were grown in the 
presence of GF alone� were integrated �n = �6 in every 
case�. Res�lts represented the mean absol�te cells 
n�mber ± SD of six different experiments on 7th� �4th� 
and ��st day of c�lt�ring. We did not observe significant 
difference in cells n�mber when СD�4+ cells were c�lti-
vated in ser�m-containing c�lt�re medi�m� and the total 
amo�nt of cells was �.� ± �.�7 x ��4� �.55 ± �.�� x ��4 
and �.5 ± �.�� x ��4 on 7th� �4th and ��st day� respec-
tively. The presence of both donors’ and patients’ MSCs 
layer witho�t GF had no effect on significant differences 
of absol�te n�mber of growing cells d�ring �� days. Total 
amo�nt of cells in the presence of donors MSCs was 
�.5 ± �.6 x ��4� �.� ± �.� x ��4 and �.� ± �.� x ��4 on 7th� 
�4th and ��st day� respectively� and in the presence of 
patients’ MSCs was �.� ± �.7 x ��4� �.75 ± �.7 x ��4 and 
�.6 ± �.� x ��4 on 7th� �4th and ��st day� respectively. The 
presence of cytokines in c�lt�re medi�m significantly 
increased the absol�te n�mber of cells from � x ��4 to 
�5.5 ± �.5 x ��4� to 5� ± ��.� x ��4 and to ���.5 ± ��.� x ��4 
on day 7� �4 and �� respectively� p < �.�5. The increase 
of total cells n�mber when CD�4+ cells were c�lt�red 
in the presence of both donors’ and patients’ MSCs 
and cytokines was the most evident� and total n�mber 
of cells in the presence of donors’ MSCs increased from 
� x ��4 to �4 ± 4.� x��4� to 94 ± 7.7 x ��4 and to �95 ± 
�4.7 x ��4 on day 7� �4 and �� respectively� p < �.�� 
and with patients’ MSCs from � x ��4 to �4 ± �.� x ��4� 
to �5 ± �.� x ��4 and to �6� ± 7.� x ��4 on day 7� �4 and 
��� respectively� p < �.��. No statistical difference was 
fo�nd between effects of patients’ and donors’ MSCs 
of on hematopoietic stem cells expansion.
To compare the f�nctional ability of donors’ and 
patients’ MSCs to s�pport proliferation of CD�4+ cells� 
we calc�lated the fold increase of cells n�mber �cells 
n�mber at the o�tp�t/cells n�mber initial� for each 
c�ltivation variant �Fig. ��. The greatest fold increase 
was observed when CD�4+ cells were c�lt�red in me-
di�m containing GF complex on 7th day� with f�rther 
increase on �4th and then ��st day. Active proliferation 
was typical for CD�4+ cells in any c�ltivation variant. 
The cells n�mber of CD�4+ cells from healthy donors 
with GF alone increased from ��.�-fold to 74.6-fold 
and to �55.� fold on 7th��4th and ��st day� respec-
tively� and for patients from ��.�-fold to �6.�-fold and 
to ��6.4-fold on day 7th��4th and ��st� respectively. 
While c�lt�ring cells with both GF and healthy donors 
MSCs layer� hematopoietic cells n�mber increased 
from �6.�-fold to ���.�-fold and to ���.5-fold on day 
7th� �4th and ��st� respectively� and both GF and pa-
tients’ MSCs layer — from ��.9-fold to �5.�-fold and 
to �6�.�-fold on 7th� �4th and ��st day� respectively.
On 7th� �4th and ��st day� the n�mber of c�lt�red 
cells in the presence of both GF and MSCs layer was 
significantly greater when compared with GF alone� 
p < �.�5� both for healthy donors’ and patients’ MSCs. 
The increase of the n�mber of hematopoietic cells in 
the presence of donors’ MSCs layer compared with ab-
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Fig. 2. Effects of several cytokines� and donors’ and patients’ MSCs on ex vivo expansion of hematopoietic stem cells. BM CD�4+ cells were 
c�lt�red in fo�r c�ltivation variants: (a) Hematopoietic cells in ser�m-containing c�lt�re medi�m; (b) CD�4+ cells with GF. CD�4+ cells on 
feeder layer of donors’ and patients’ MSCs; (c) CD�4+ cells with growth factors on feeder layer of donors’ and patients’ MSCs; (d) The res�lts 
represent the mean cells n�mber ± SD of 6 different experiments on days 7� �4 and ��.  MSCs of patients;  MSCs of healthy donors
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sence of MSCs layer was �6 vs ��.�-fold� respectively� 
�p < �.��� on 7th day� ���.� vs 74.6-fold �p < �.��� on 
�4th day� and ���.5 vs �55.�-fold on ��st day. C�lt�ring of 
CD�4+ cells with patients’ MSCs layer also demonstrated 
the significantly greater increase of hematopoietic cells 
n�mber on 7th� �4th and ��st day as compared with 
absence of MSCs layer:��.9 vs ��.�-fold� respectively� 
�p < �.�5� on 7th day� �5.5 vs �6.�-fold �p < �.�5� on �4th 
day and �6�.� vs ��6.4-fold �p < �.��� on ��st day. 
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Fig. 3. MSCs layer significantly increased proliferation of CD�4+ 
cells c�lt�red in medi�m with GF in comparison with CD�4+ 
cells grown in c�lt�re medi�m or c�lt�red in the presence of GF 
alone. After 7th� �4th and ��st days cells were harvested� and 
the fold increase was calc�lated. For statistical analysis� Mann — 
Whitney U test was �sed to compare the effect of donors MSCs 
and MSCs of patients on fold increase of hematopoietic cells 
�*p < �.�5� **p < �.���
Statistical analysis �Mann — Whitney U test� com-
paring the fold increase in the n�mber of cells for two 
independent gro�ps of donors and patients didn’t 
detect statistically valid difference between the effects 
on hematopoietic cells proliferation of co-c�lt�red for 
� weeks donors’ MSCs and patients’ MSCs derived from 
BM of patients with oncohematological diseases.
Influence of MSCs on changing of the cell 
population profile after CD34+ cells expansion. 
MSCs infl�ence on changing of CD�4+ cells pop�lation 
profile after cells expansion was st�died by c�lt�ring 
cells in liq�id LTC medi�m in presence of GF alone or 
combined with MSCs for � weeks� �sing clonogenic 
assay progenitors in methylcell�lose. 
Morphological analysis of colony forming cells �CFC� 
demonstrated the existence of pl�ripotent hematopoie-
tic prec�rsor cells CFU-GEMM� bypotential prec�r-
sors — CFU-GM and committing prec�rsors CFU-G� 
CFU-M� BFU-E. All types of colony-forming �nits �CFU� 
were scored and res�lts presented in Table. A mean 
total of 579 CFC/��4 CD�4+ cells was observed in initial 
samp les: ��% of cells ���5/��4 CD�4+ cells� corre-
sponded to CFU-G� �5% ��9/��4 CD�4+ cells� to CFU-
M� 4% ���/��4 CD�4+ cells� to CFU-GM� 49% ��6�/��4 
CD�4+ cells� to BFU-E� and �.�% ��.6/��4 CD�4+ cells� 
to m�ltipotent progenitor cells �CFU-GEMM�. A mean 
total of �5� CFU/��4 CD�4+ cells was observed after ex-
pansion CD�4+ cells in c�lt�ral medi�m in the pre sence 
of GF alone �pon a �-week c�lt�ring period. CFU com-
prised ��% of CFU-G� 6�% of CFU-M� 5.�% of CFU-GM� 
�.�% of CFU-GEMM. When CD�4+ cells were grown in 
the presence of the GF together with MSCs layer� the 
spectr�m of CFU was: 4�% of CFU-G� 4�% of CFU-M� 
��% of CFU-GM� �.6% of CFU-GEMM. 
Table. Effect of MSCs on population profile of hematopoietic progenitors 
throughout a 3-week culturing period
CD34+ cells
Progenitor cells per 1 x 104 CD34+ cells plated 
(mean ± SEM)
CFU-G CFU-M CFU-GM CFU-GEMM BFU-E
Initial cells (n = 9) 185 ± 73 89 ± 39 23 ± 17 0.6 ± 0.3 282 ± 119
Expansion with GF 
(n = 7)
80.5 ± 35 155.5 ± 53 13 ± 6 0.7 ± 0.36 ND 
Expansion with 
GF+MSCs (n = 7)
113 ± 32 135.5 ± 64 31 ± 12 1.6 ± 0.7 ND 
ND — not detected.
Th�s� o�r findings indicated that the dominant pop�-
lations of hematopoietic prec�rsors proliferated in vitro, in 
initial samples and c�lt�red for �� days� were committing 
prec�rsors CFU-G and CFU-M. The proportion of CFU-G/
CFU did not differ before and after CD�4+cells expansion 
for �� days witho�t MSCs layer ���% vs ��%� or with 
MSCs layer ���% and 4�%�. The proportion of CFU-M/
CFU increased after CD�4+cells expansion for �� days 
witho�t MSCs layer from �5% to 6�% and with MSCs 
layer from �5% to 4�% compared to CD�4+cells initial.
The proportion of immat�re CFU-GM and pl�ripo-
tent CFU-GEMM prec�rsors to total CFU increased af-
ter hematopoietic stem cells c�ltivation witho�t MSCs 
layer and in the presence of MSCs compared to initial 
samples: for CFU-GM from 4% to 5% and from 4% to 
��%� respectively� and for CFU-GEMM from �.�% to 
�.�% and from �.�% to �.6%� respectively.
Relative changes of progenitors n�mber in CD�4+ 
cell pop�lation after expansion for � weeks in presence 
MSCs layer to n�mber of corresponding compartment 
of CFU in initial samples of CD�4+ cells is shown on Fig. 4. 
Relative changes of CFU-GM and CFU-GEMM n�mber 
after c�ltivation both with MSCs and witho�t MSCs did 
not differ significantly from n�mber of CFU-GM and 
CFU-GEMM in initial pop�lation of CD�4+ cells. Tho�gh 
n�mber of CFU-GM and CFU-GEMM were greater ap-
proximately by �.5-fold after expansion in the presence 
of MSCs layer than witho�t MSCs �p < �.�5�. BFU-E 
wasn’t detected in any analyzed sample after expansion 
of CD�4+ cells �nder the described c�lt�ring conditions 
for three weeks� while BFU-E n�mber consisted 49% 
����.6 ± �59.�� in initial pop�lation of CD�4+ cells.
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Fig. 4. Relative changes of hematopoietic progenitors n�mber 
after expansion of CD�4+ cells for �� days in presence of MSCs 
layer. Corresponding compartments of CFU in initial samples of 
CD�4+ cells recognized as � �n = 9; *p < �.�5�
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DISCUSSION
In this work we examined the potential of MSCs 
derived from the bone marrow of children with onco-
hematological diseases� treated by high-dose poly-
chemotherapy and radiotherapy� to s�pport hematopoi-
etic progenitors proliferation in vitro. It is important 
for creation of a therape�tical strategy of application 
of a�tologo�s MSCs for ne�tropenia period red�ction 
after HSCs a�tologo�s transplantation for children with 
ins�fficient n�mber of CD�4+ cells in graft.
In some p�blications it was demonstrated that BM 
stroma greatly damaged after high-dose chemotherapy 
or radiotherapy [��� ��]. Patients stromal cells c�lt�red 
for 4�5 weeks after conditioning regimen� incl� ding 
b�s�lphan and cyclophosphamide� are able to give 
a monolayer only in ��% of cases in comparison with 
��% shown for healthy donors [�4]. However� we �sed 
proced�re of MSCs isolation and expansion from BM 
of children with malignant neoplasms� and increased 
initial n�mber of cells for more than � х ���-fold� as it 
was demonstrated in o�r previo�s work [�5].
The ability of MSCs to s�pport hematopoiesis 
in vitro has been shown by many a�thors in experi-
ments �nder the conditions of sim�ltaneo�s c�ltivation 
of MSCs and HSCs [�6���].
Dexter et al were among the first researchers� who 
st�died the infl�ence of stromal layer on proliferation 
of BM cells. They had shown that stromal cells s�p-
ported hematopoietic cells proliferation and creation 
of colony-forming �nit spleen �CFU-S�� while CFU-S 
were absent when hematopoietic cells were c�ltivated 
witho�t stromal layer [�9]. 
Some st�dies examined the capacity of c�ltivated 
MSCs to s�pport h�man hematopoiesis in vitro. They 
revealed that not only committed cells b�t also primi-
tive hematopoietic prec�rsors are able to proliferate 
�nder the contact with MSCs. Th�s� hematopoietic 
prec�rsors maintained the ability not only to differen-
tiate b�t also to self-replicate [��]. Wagner et al veri-
fied that primitive fractions of HPC had m�ch stronger 
adherence to BM-derived MSCs than their more diffe-
rentiated co�nterparts� and that LTC-IC freq�ency was 
higher in the adherent fraction than in the nonadherent 
fraction of CD�4+ cells [��]. 
Koller et al and Breems et al demonstrated that 
stromal cells significantly increased the n�mber of pro-
genitor and primitive stem cells after expansion of BM-
derived СD�4+ cells for � weeks in presence of IL-�� SCF� 
GM-CSF� and erythropoietin. C�ltivation ex vivo red�ced 
the ability of CD�4+ cells to prod�ce progenitors in LTC 
witho�t stromal sol�ble factors or in presence of stromal 
cells. The best expansion of CFU and LTC-IC and optimal 
maintenance of graft q�ality were observed when PBSC 
were c�lt�red in stroma-contact [�� ����4]. On the other 
hand� Verfaillie et al demonstrated significantly worse 
recovery of LTC-IC from c�lt�res� in which progenitors 
were grown in contact with stroma. Also� researchers 
have shown that direct contact with stroma inhibited 
proliferation of LTC-IC even in case of gl�taraldehyde-
fixed stroma� which was no longer capable for prod�cing 
growth inhibitory or stim�latory cytokines [�5]. At the 
same time� Harvey et al showed that direct cell-to-cell 
contact between HSCs and �rogenital ridge derived 
stromal cells increased the CFU-C n�mbers 5 times 
compared with non-contact co-c�lt�re [�6].
O�r observations of hematopoietic stem cells ex-
pansion in semisolid medi�m witho�t growth cytokines 
in vitro testified that the presence of MSCs derived 
from BM of patients with oncohematological disease 
increased the n�mber of committing myeloid progeni-
tors approximately �-fold �p < �.�5�. The most intensive 
proliferative activity of progenitor cells was shown in the 
presence of patients’ MSCs and GF �SCF� GM-CSF� IL-�� 
and EPO�. In this case� we detected 7-fold increase in 
the n�mber of myeloid progenitors and �4-fold in the 
amo�nt of earlier pl�ripotent hematopoietic prec�rsor 
cells �CFU-GEMM� compared with hematopoietic stem 
cells expansion in methylcell�lose medi�m witho�t 
MSCs and cytokines. These findings are in line with 
data obtained for hematopoiesis s�pporting f�nction 
of MSCs derived from BM of healthy donors� and with 
statistical validity reveal that s�pporting effect on pro-
liferation of pl�ripotent hematopoietic prec�rsor cells 
�CFU-GEMM� of patients’ MSCs did not differ from 
s�pporting effect of MSCs from healthy donors.
In the present work we also st�died the effect of MSCs 
layer from patients’ BM on maintaining of hematopoietic 
stem cells proliferation in liq�id LTC medi�m containing 
a combination of several cytokines. We revealed that the 
presence of MSCs layer significantly promoted the rate 
of hematopoietic cells proliferation on 7th� �4th and ��st 
days� and total cells n�mber was m�ltiplied �6�.�-fold 
on ��th day as compared with ��6.4-fold in the absence 
of MSCs layer. Similar data was obtained when CD�4+ 
cells were grown on donors’ MSCs layer� and the cells 
n�mber increased ���.5-fold in the presence of MSCs 
layer compared to �55.�-fold witho�t MSCs. 
Interestingly� o�r st�dy of hematopoietic stem cells 
proliferation kinetics �nder vario�s c�lt�ring conditions 
demonstrated that the presence of both patients’ and 
donors’ MSCs layers witho�t GF didn’t have significant 
infl�ence on expansion of hematopoietic cells within 
a � week. At the same time� we showed that MSCs 
from BM of both oncohematological patients and 
healthy donors didn’t inhibit proliferation of commit-
ted progeni tors and primitive stem cells even if СD�4+ 
cells were c�ltivated in the absence of growth factors� 
whereas in case of growing СD�4+ cells witho�t cytoki-
nes and MSCs we observed a loss of hematopoietic 
cells. This fact confirmed the role of MSCs in preven-
tion of HSCs apoptosis [�7� ��].
It is very important that when CD�4+cells were c�l-
t�red both in semisolid medi�m or in liq�id LTC medi�m 
the capacity of MSCs derived from BM patients with 
oncohematological diseases to s�pport proliferation 
and self renewal of hematopoietic prec�rsor cells 
was the same as of MSCs derived from bone marrow 
of healthy donors.
In the present work we st�died the cell pop�lation 
profile �pon � weeks of CD�4+ cells expansion in LTC 
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medi�m. Cells were c�ltivated with cytokines alone 
or both cytokines and MSCs. We observed that MSCs 
presence did not alter the pop�lation of committed 
CFU-G and CFU-M prec�rsors as compared with initial 
pop�lation of CD�4+ cells. The significant increase 
in proportion of more primitive bipotent prec�rsors 
�CFU-GM� and pl�ripotent �CFU-GEMM� prec�rsors 
in the pop�lation of hematopoietic cells after CD�4+ 
cells expansion in the presence of MSCs layer is a very 
important finding. Altogether� obtained res�lts are 
in line with concl�sions made by other researchers 
that stromal cells s�pport self-renewal of progenitor 
compartment b�t they do not alter the differentiation 
and proliferation of mat�re cells [��]. 
It is important that in o�r st�dy of prec�rsor cells 
pop�lation grown for � weeks from isolated CD�4+ 
cells we observed a complete disappearance of 
erythroid progenitors independently of MSCs layer 
presence� whereas other a�thors� who st�died kinetics 
of different hematopoietic progenitor cells in standard 
long-term dextertype c�lt�res revealed a loss of sig-
nificant amo�nt of erythroid progenitors in 5 weeks 
and the complete absence of these cells in 7 weeks. 
The probable reason of disappearance of erythroid 
progenitors in o�r st�dy co�ld be in the high amo�nt of 
cytokines� s�ch as Flt-�-ligand� in the c�lt�ral medi�m� 
which provided the shift towards myelopoiesis.
In s�mmary� we explored f�nctional potential of 
МSCs derived from BM of children with malignancies 
after high-dose chemotherapy or radiation to maintain 
hematopoiesis in vitro and came to the concl�sion that 
efficacy of patients’ MSCs to s�pport the proliferation 
and self-renewal of hematopoietic cells was not diffe-
rent from MSCs derived from bone marrow of healthy 
donors. In o�r st�dy all experiments with МSCs derived 
from BM of patients with oncological disorders and 
BM of donors were performed in identical conditions� 
and both types of MSCs were derived and expanded 
�sing common protocol. Moreover� a�tologo�s 
MSCs of patients who were the candidates for HSCs 
transplantation� similarly to donors’MSCs� greatly 
increased the n�mber of more primitive bipotent mye-
loid and pl�ripotent prec�rsors� while co-c�ltivated 
with hematopoietic stem cells. Th�s� we consider that 
co-transplantation of a�tologo�s MSCs is good way 
to improve hematopoietic stem cells engraftment and 
red�ce a period of gran�locytopenia after a�tologo�s 
HSCs transplantation in case of ins�fficient CD�4+ cell 
n�mber in a�tologo�s transplant.
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ВЛИЯНИЕ МЕЗЕНХИМАЛЬНЫХ СТВОЛОВЫХ КЛЕТОК 
ИЗ КОСТНОГО МОЗГА ДЕТЕЙ С ОНКОЛОГИЧЕСКИМИ 
И ГЕМАТОЛОГИЧЕСКИМИ ЗАБОЛЕВАНИЯМИ 
НА ПРОЛИФЕРАЦИЮ И СПОСОБНОСТЬ 
К САМОПОДДЕРЖАНИЮ КЛЕТОК —ПРЕДШЕСТВЕННИКОВ 
ГЕМОПОЭЗА IN VITRO
Цель: исследовали способность культивируемых in vitro мезенхимальных стволовых клеток (МСК), выделенных из костного 
мозга детей со злокачественными новообразованиями, получавших в качестве лечения высокодозовую полихимиотерапию, 
поддерживать гемопоэз in vitro. Материалы и методы: МСК выделяли и наращивали из проб костного мозга 8 пациентов 
и 9 здоровых доноров детского возраста. CD34+ клетки выделяли из проб костного мозга доноров. Были поставлены 
эксперименты по совместному культивированию МСК и CD34+ клеток в среде метилцеллюлозы и в среде для долгосрочного 
культивирования с добавлением цитокинов и при их отсутствии. Результаты: в метилцеллюлозной среде наличие МСК 
пациентов увеличивало количество коммитированных миелоидных предшественников в 2 раза, МСК совместно с ростовыми 
факторами стимулировало пролиферацию этого типа клеток в 7 раз, а полипотентных предшественников — в 14 раз. При 
долгосрочном культивировании с цитокинами на слое МСК общее количество ГСК на 21­й день возростало в 161,2 раза. При 
пролиферации CD34+ клеток в среде с МСК содержание бипотентных КОЕ­ГМ повысилось с 4 до 11%, а полипотентных 
КОЕ­ГЭММ — с 0,1 до 0,6%. В экспериментах по экспансии CD34+ клеток результаты при использовании в качестве 
фидерного слоя МСК пациентов или МСК доноров статистически не отличались. Выводы: проведенные исследования 
позволяют сделать вывод о том, что МСК из костного мозга пациентов со злокачественными новообразованиями обладают 
достаточным функциональным потенциалом для пролиферации и самоподдержания ГСК. Ко­трансплантация аутологичных 
МСК при аутотрансплантации ГСК с низким содержанием CD34+ клеток в трансплантате может являться перспективной 
для сокращения периода восстановления гемопоэза в ранний посттрансплантационный период. 
Ключевые слова: мезенхимальные стволовые клетки, злокачественные новообразования, гемопоэз, предшественники 
гемопоэза.
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